PSMA-targeted RLT is reshaping the treatment landscape for prostate cancer, expanding treatment options for patients with advanced prostate cancer and contributing to improved outcomes and quality of life, both in clinical trials and in routine practice [37]. The gene discussed is FOLH1; the disease is Familial prostate cancer.